This page summarizes published sources for information only. It is not medical advice and does not tell anyone to use a product. Questions about your own health belong with a licensed clinician. For questions about an order or a product, contact us.
| Rybelsus | Semaglutide | |
|---|---|---|
| What it is | A brand-name tablet that contains semaglutide1 | The active ingredient: a lab-made analog of the hormone GLP-1, with a 94% sequence match3 |
| Active ingredient | Semaglutide, with the absorption enhancer salcaprozate sodium (SNAC)1 | Semaglutide itself, a peptide with the formula C187H291N45O594 |
| Maker | Novo Nordisk1 | Novo Nordisk, maker of Ozempic, Wegovy and Rybelsus781 |
| Form | Once-daily tablets of 3, 7 and 14 mg1 | Weekly injections (Ozempic, Wegovy) or daily tablets (Rybelsus, Ozempic tablets, Wegovy tablets)7819 |
| Approved uses | Adults with type 2 diabetes: blood sugar control, and lower risk of major cardiovascular events in those at high risk1 | By product: type 2 diabetes with heart and kidney uses, weight reduction, heart risk in adults with cardiovascular disease and obesity or overweight, and MASH78 |
| Dosing schedule | 3 mg daily for 30 days, then 7 mg; 14 mg from day 61 if more control is needed1 | Injections from 0.25 to 7.2 mg weekly and tablets from 1.5 to 25 mg daily, depending on the product131 |
| First US approval | September 20, 20192 | December 5, 2017, as Ozempic injection6 |
Key differences
Rybelsus is semaglutide in tablet form, combined with an ingredient that helps it get absorbed from the stomach.1 The molecule itself is the same one given by weekly injection as Ozempic and Wegovy.78 What changes with the tablet is the route, the dose scale and the daily routine.
What semaglutide is
Semaglutide is a modified copy of the hormone GLP-1, sharing 94% of its sequence with the human version.3 It stimulates insulin release and lowers glucagon in a glucose-dependent way, and causes a minor delay in stomach emptying after meals.3 Its peptide backbone is made by yeast fermentation, with a C18 fatty diacid joined through a spacer to the lysine at position 26.4 Its molecular weight is 4113.58 g/mol, and its half-life is about one week.41
Absorption and the dose scale
Very little of a swallowed dose reaches the blood: the label estimates 0.4% to 1% for Rybelsus and 1% to 2% for Ozempic tablets, absorbed mostly in the stomach, with blood levels peaking about 1 hour after a dose.1 After an injection under the skin, 89% is absorbed.5 The dose scales sit far apart: Rybelsus maintenance doses are 7 or 14 mg a day, while injected semaglutide runs from 0.25 mg to 7.2 mg a week.113
Both tablets contain salcaprozate sodium (SNAC), an absorption enhancer, and magnesium stearate; Rybelsus also contains microcrystalline cellulose and povidone.1
A strict morning routine
The label is precise about how the tablet is taken. One tablet goes down each morning on an empty stomach, with no more than 4 ounces of plain water, swallowed whole.1 Then comes a wait of at least 30 minutes before any food, drink or other oral medicine.1 In studies of healthy people, more semaglutide was absorbed with 50 mL of water than with 240 mL, and with a longer wait before eating.1 A missed tablet is skipped, and the next one is taken the following day.1
Dose steps
Rybelsus starts at 3 mg once daily for 30 days, a starting dose the label says is not effective for blood sugar control.1 On day 31 it rises to 7 mg, and from day 61 it can go to 14 mg, the highest Rybelsus strength, if more control is needed.1 Only one tablet is taken per day, and the prescriber sets each step.1 Steady blood levels take 4 to 5 weeks of daily dosing to build.1
Three tablet products now share the molecule
"Semaglutide tablets" no longer means only Rybelsus. A second, round formulation was approved on December 9, 2024, and renamed Ozempic tablets on January 30, 2026; it comes in 1.5, 4 and 9 mg.11101 Wegovy tablets of 1.5, 4, 9 and 25 mg were approved on December 22, 2025, for weight reduction and heart risk in adults.98 Rybelsus and Ozempic tablets share one label but are not swapped milligram for milligram, and the label gives a separate switching table.1
What Rybelsus is approved for
Rybelsus is a diabetes medicine. FDA approved it on September 20, 2019, to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise.21 On October 17, 2025, FDA added a second use: lowering the risk of major cardiovascular events in adults with type 2 diabetes at high risk.12
Rybelsus is not approved for weight loss.1 In its 26-week diabetes trials, weight fell 2.2 to 4.4 kg on Rybelsus 7 or 14 mg and 0.4 to 1.4 kg on placebo.1
Other semaglutide products cover more ground. Ozempic injection adds a kidney indication for adults with type 2 diabetes and chronic kidney disease.7 Wegovy is approved for weight reduction, for heart risk in adults with established cardiovascular disease and obesity or overweight, and for the liver disease MASH.8
Trials behind the tablet
The label's blood sugar results come from 26-week trials against placebo and against three other diabetes drugs.1 Rybelsus 14 mg lowered HbA1c by 1.3 points against 0.9 for empagliflozin, and by 1.3 points against 0.8 for sitagliptin.1 Against daily liraglutide injection, it lowered HbA1c by 1.2 points against 1.1, with more weight loss (4.4 kg against 3.1 kg).1 In 324 adults with moderate kidney impairment, mean age 70, 14 mg lowered HbA1c by 1.0 point against 0.2 on placebo.1 Added to insulin in 731 adults, 7 or 14 mg lowered HbA1c by 0.9 to 1.3 points against 0.1.1
Safety points tied to the tablet
Rybelsus carries a boxed warning for thyroid C-cell tumors, which semaglutide caused in mice and rats; whether it does so in people is unknown.1 Breastfeeding advice comes from the tablet itself. In a lactation study, semaglutide in breast milk was too low to measure, but SNAC or its breakdown products are present in human milk and could build up in the infant. Because semaglutide products without SNAC exist, the label says breastfeeding is not recommended while taking Rybelsus or Ozempic tablets.1 The label also notes that slower stomach emptying can change how other pills are absorbed: levothyroxine exposure rose 33% when taken with semaglutide tablets.1
Storage is simple. Rybelsus is kept at room temperature, 68 to 77°F, in its original closed bottle to protect it from moisture, and not moved to any other container.1
Which page to read next
The Rybelsus profile has the full label, and the semaglutide profile covers the molecule and its research. Doses step by step are in Rybelsus dosage, and trial side effect rates in Rybelsus side effects. For the weekly injection against the daily tablet, read Ozempic vs Rybelsus. Other ingredient pairs include Ozempic vs semaglutide and semaglutide vs Wegovy, and the GLP-1 comparisons page has the full list.
Frequently asked questions
Can you get semaglutide in a tablet?
Yes. As of October 2026, three FDA-approved products are semaglutide tablets taken once a day.29 Rybelsus (3, 7 and 14 mg) and Ozempic tablets (1.5, 4 and 9 mg) are for adults with type 2 diabetes.1 Wegovy tablets (1.5, 4, 9 and 25 mg) are for weight reduction and heart risk in adults.98 All three are prescription medicines, and each has its own starting dose and steps.29113
Do I need a prescription for semaglutide pills?
Yes, in the US. FDA lists every strength of Rybelsus, Ozempic tablets and Wegovy tablets with the marketing status Prescription.29 Each tablet starts at a low dose that is raised in steps, and the prescriber decides the dose and when to change it.113 Rybelsus and Ozempic tablets are not interchangeable milligram for milligram, so a switch between them follows the label's switching table rather than matching numbers.1
What is Rybelsus 3 mg used for?
Only for starting treatment. The label gives 3 mg once daily for days 1 to 30 as the starting dose, and says this dose is not effective for blood sugar control.1 On day 31 the dose rises to 7 mg, and from day 61 it can rise to 14 mg if more control is needed.1 The slow step-up is meant to reduce stomach and gut side effects, and the prescriber sets each change.1
Is Rybelsus the same as semaglutide?
Rybelsus is semaglutide in one particular form. Semaglutide is the active ingredient, also used in the Ozempic and Wegovy injections and tablets.781 Rybelsus is a 3, 7 or 14 mg tablet that adds the absorption enhancer SNAC and is taken daily for type 2 diabetes.1 Its milligram doses do not carry over to other semaglutide products: an injection is absorbed far more completely than a tablet, and even Ozempic tablets are not swapped with Rybelsus milligram for milligram.15
Written by D2C Peptides Editorial Team.
Pending qualified review.
Updated .
Sources
- RYBELSUS and OZEMPIC (semaglutide) tablets, Prescribing Information and Medication Guide (NDA 213051/S-030, revised 1/2026). U.S. Food and Drug Administration (Novo Nordisk labeling), 2026.
- Drugs@FDA: NDA 213051, Rybelsus and Ozempic (semaglutide) tablets, application overview. U.S. Food and Drug Administration, 2026.
- OZEMPIC (semaglutide) injection prescribing information, section 12.1 Mechanism of Action. DailyMed, U.S. National Library of Medicine (Novo Nordisk label, revised 5/2026), 2026.
- Same source as 3: section 11 Description.
- WEGOVY (semaglutide) prescribing information, section 12.3 Pharmacokinetics (absorption). DailyMed, U.S. National Library of Medicine (Novo Nordisk label, revised 6/2026), 2026.
- Drugs@FDA: OZEMPIC, NDA 209637. U.S. Food and Drug Administration.
- Same source as 3: Indications and Usage; DailyMed listing.
- Same source as 5: WEGOVY (semaglutide) injection and tablets prescribing information, section 1 Indications and Usage.
- Drugs@FDA: WEGOVY tablets, NDA 218316. U.S. Food and Drug Administration.
- Supplement approval letter, NDA 213051/S-030 (name change of Rybelsus formulation R2 to Ozempic tablets). U.S. Food and Drug Administration, 2026.
- Supplement approval letter, NDA 213051/S-020 and S-021 (Rybelsus formulation R2). U.S. Food and Drug Administration, 2024.
- Supplement approval letter, NDA 213051/S-024, S-028, S-029 (cardiovascular risk reduction indication). U.S. Food and Drug Administration, 2025.
- Same source as 5: WEGOVY (semaglutide) injection and tablets prescribing information, section 2 Dosage and Administration.